Overview

To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks

Status:
Recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

Glucocorticoids are effective in the treatment of rheumatoid arthritis, but long-term use of glucocorticoids has many side effects. Tofacitinib is a new small-molecule drug targeting JAK, which has been found to act quickly. The aim of this clinical trial was to investigate the efficacy and safety of tofacitinib and low-dose glucocorticoids in inducing remission in patients with rheumatoid arthritis with moderate to high disease activity.

Phase:

Phase 4

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators:

Jiaxing Hospital of T.C.M
Jinhua Municipal Central Hospital
SAHZU.CHANGXING CAMPUS
Shaoxing People's Hospital
Zhuji People's hospital

Treatments:

Glucocorticoids
Tofacitinib